Real-world outcomes of pomalidomide therapy after lenalidomide induction in relapsed/refractory multiple myeloma

泊马度胺 来那度胺 医学 多发性骨髓瘤 内科学 肿瘤科 队列 耐火材料(行星科学) 进行性疾病 沙利度胺 外科 疾病 天体生物学 物理
作者
Tomer M. Mark,Angelica Falkenstein,Jonathan Kish
出处
期刊:Future Oncology [Future Medicine]
卷期号:18 (5): 553-564 被引量:5
标识
DOI:10.2217/fon-2021-1176
摘要

Aim: To demonstrate the efficacy of pomalidomide for relapsed/refractory multiple myeloma (RRMM) following treatment in real-world, community practice using retrospective database analysis. Materials & methods: US-based community oncologists identified patients with RRMM treated with or without pomalidomide following first-line lenalidomide. Disease response (≥ very good partial response) and progression-free survival were compared. Results: Disease response was 78.6 and 51.7% for pomalidomide (n = 126) and nonpomalidomide cohorts (n = 174), respectively (p < 0.0001). Multivariate adjusted odds of response were 4.5-times greater for pomalidomide cohort (p < 0.0001). Median progression-free survival was not reached for pomalidomide cohort and 16.7 months for nonpomalidomide cohort (log-rank p < 0.01). Conclusion: Following lenalidomide induction in RRMM, pomalidomide is an effective treatment.Plain language summary Treatment options have expanded in recent years for patients with relapsed/refractory multiple myeloma (RRMM) who received lenalidomide as their initial treatment and then either had a period of improvement before the disease worsened or did not respond to the medication at all. Pomalidomide is another MM treatment from the same drug class as lenalidomide. We analyzed the effect of a combination treatment containing pomalidomide versus a combination treatment without pomalidomide in patients with MM who had received routine initial treatment with lenalidomide. US-based community oncologists completed study forms to record patient characteristics and treatment response information. Results showed that patients who received pomalidomide in a combination treatment after initial lenalidomide treatment achieved higher rates of very good partial response or better and longer progression-free survival than those who did not. The results of this analysis suggest that switching to a different class of drugs following the initial treatment may not be warranted after first relapse and pomalidomide-containing combination treatments are a more effective treatment following lenalidomide for patients with RRMM.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
谢琉圭发布了新的文献求助10
2秒前
wu发布了新的文献求助10
3秒前
打滚完成签到,获得积分10
4秒前
LJJ发布了新的文献求助10
4秒前
睡觉了完成签到 ,获得积分10
6秒前
量子星尘发布了新的文献求助10
7秒前
乖猫要努力应助精明寻梅采纳,获得10
7秒前
AI完成签到,获得积分10
10秒前
xiaosu发布了新的文献求助30
11秒前
11秒前
谢琉圭完成签到,获得积分10
13秒前
领导范儿应助稳重的若雁采纳,获得10
16秒前
16秒前
17秒前
wu完成签到,获得积分20
17秒前
momo发布了新的文献求助10
18秒前
19秒前
田様应助123采纳,获得10
19秒前
23秒前
zying完成签到,获得积分10
26秒前
27秒前
双楠应助wangjue采纳,获得10
27秒前
32秒前
雪白尔岚发布了新的文献求助10
36秒前
36秒前
36秒前
慕青应助momo采纳,获得10
37秒前
从容冰夏完成签到,获得积分10
39秒前
39秒前
桐桐应助Candy采纳,获得10
40秒前
YR完成签到,获得积分10
42秒前
欧阳月空发布了新的文献求助10
42秒前
周em12_发布了新的文献求助10
43秒前
糊涂涂完成签到 ,获得积分10
43秒前
44秒前
46秒前
Zhang完成签到,获得积分10
47秒前
48秒前
48秒前
49秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989334
求助须知:如何正确求助?哪些是违规求助? 3531428
关于积分的说明 11253936
捐赠科研通 3270119
什么是DOI,文献DOI怎么找? 1804887
邀请新用户注册赠送积分活动 882087
科研通“疑难数据库(出版商)”最低求助积分说明 809173